You are here

Clinical Trials: Cord Blood

Comment

Discuss
Body: Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aggressive Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified July 2017
Body: Conditions:   MDS;   Anemia, Aplastic;   Inborn Errors of Metabolism;   Congenital Marrow Failure;   Congenital Immunodeficiency Syndrome
Intervention:   Biological: ALDHbr Umbilical Cord Blood Cells
Sponsors:   Joanne Kurtzberg, MD;   Aldagen
Completed - verified April 2017
Body: Conditions:   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: Fludarabine;   Drug: mycophenolate mofetil;   Radiation: total marrow irradiation;   Procedure: umbilical cord blood transplantation;   Biological: Granulocyte colony-stimulating factor;   Biological: HLA-matched related donor bone marrow
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed - verified July 2017
Body: Condition:   Fanconi Anemia
Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2017
Body: Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting
Body: Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified December 6, 2016
Body: Condition:   Chronic Granulomatous Disease
Interventions:   Drug: Busulfan;   Biological: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Procedure: Stem Cell Infusion
Sponsors:   Baylor College of Medicine;   Texas Children's Hospital
Active, not recruiting - verified July 2017
Body: Condition:   Lymphoma
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: gemcitabine hydrochloride;   Drug: ifosfamide;   Drug: mechlorethamine hydrochloride;   Drug: melphalan;   Drug: methotrexate;   Drug: mycophenolate mofetil;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Drug: vinorelbine tartrate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Memorial Sloan Kettering Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified May 2017
Body: Conditions:   Leukemia;   Lymphoma;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Active, not recruiting - verified August 2017
Body: Condition:   Graft Versus Host Disease
Intervention:   Drug: Interleukin-2
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Novartis
Active, not recruiting
Body: Condition:   Inherited Immune Deficiencies
Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 1, 2016
Body: Conditions:   Sickle Cell Disease;   Beta Thalassemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
Sponsor:   Columbia University
Recruiting - verified July 2017
Body: Condition:   Hodgkin's Disease
Interventions:   Drug: Gemcitabine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Antithymocyte Globulin;   Procedure: Allogeneic Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Filgrastim (G-CSF);   Drug: Methotrexate
Sponsor:   M.D. Anderson Cancer Center
Completed
Body: Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2017
Body: Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: aldesleukin;   Biological: filgrastim;   Biological: natural killer cell (NK) therapy;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Drug: mycophenolate mofetil;   Procedure: Umbilical Cord Blood Transplantation (UCBT);   Radiation: Total body irradiation (TBI)
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated

Pages